文献速递消化道肿瘤与早癌炎症性肠病

肿瘤相关髓系细胞中的EGFR促进小鼠结直肠癌发生并与患者结局相关

EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients.
PubMed 文献 · Gastroenterology · 2017-04-09

研究对116例结直肠肿瘤活检组织进行免疫组化分析,发现髓系细胞表达EGFR与肿瘤转移及患者生存期缩短相关。小鼠实验表明,髓系细胞而非肠上皮细胞缺失EGFR可减少ApcMin依赖及AOM/DSS诱导的肠道肿瘤形成,且髓系细胞EGFR通过STAT3和IL6信号促进肿瘤发生。

要点

  • 人结直肠肿瘤间质髓系细胞可检测到EGFR,其表达与肿瘤转移和生存期缩短相关。
  • 小鼠髓系细胞缺失EGFR后,ApcMin背景及AOM/DSS诱导的肿瘤数量更少、体积更小。
  • 髓系细胞EGFR通过激活STAT3和survivin表达促进肿瘤发生,并调控IL6表达。

核心结论

  • 结直肠肿瘤间质髓系细胞中EGFR表达升高与肿瘤进展及转移性结直肠癌患者生存期缩短相关。
  • 髓系细胞而非肠上皮细胞缺失EGFR可保护小鼠免受结肠炎诱导的肠癌及ApcMin依赖的肠道肿瘤发生。
  • 髓系细胞表达EGFR增加肠上皮细胞中STAT3活化和survivin表达以及结肠组织中IL6表达。
  • 这些发现表明结直肠肿瘤间质髓系细胞而非癌细胞本身表达的EGFR促进肿瘤发生。

研究设计与样本

  • 对116例结直肠肿瘤活检组织进行免疫组化和免疫荧光分析,检测肿瘤和间质中EGFR水平,并收集肿瘤分期、患者特征及结局信息。
  • 使用缺乏肠上皮细胞EGFR(Villin-Cre; Egfrf/f和Villin-CreERT2; Egfrf/f)或髓系细胞EGFR(LysM-Cre; Egfrf/f)的小鼠,背景为混合背景。
  • 将这些小鼠与ApcMin/+小鼠杂交;分别用右旋糖酐硫酸钠(DSS)联合或不联合氧化偶氮甲烷(AOM)诱导结肠炎相关癌症和结肠炎。
  • 通过他莫昔芬激活已形成肿瘤中的Villin-CreERT2;以表达全长EGFR的同窝小鼠作为对照。
  • 采用组织学、免疫组化、定量逆转录聚合酶链反应和流式细胞术分析评估结肠炎严重程度、肿瘤数量和大小及肠道屏障完整性。

主要发现

  • 在人结直肠肿瘤间质髓系细胞中检测到EGFR;髓系细胞EGFR表达与肿瘤转移和患者生存期缩短相关。
  • 髓系细胞缺失EGFR的小鼠在ApcMin/+背景及AOM/DSS处理后,形成的肿瘤数量显著少于且体积显著小于相应的表达EGFR的对照。
  • 肠上皮细胞缺失EGFR不影响肿瘤生长;对AOM/DSS处理后已形成肠道肿瘤的小鼠,他莫昔芬诱导上皮细胞缺失EGFR未缩小肿瘤体积。
  • 髓系细胞缺失EGFR的小鼠在DSS处理后发生更严重的结肠炎,表现为肠道炎症增加和肠道屏障破坏,较对照小鼠或肠上皮细胞缺失EGFR的小鼠更严重。
  • DSS处理的LysM-Cre; Egfrf/f小鼠结肠中EGFR缺陷髓系细胞IL6表达降低,上皮STAT3活化较对照降低;给予重组IL6可保护其免于体重下降并恢复上皮增殖和STAT3活化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Inhibitors of the epidermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorectal tumors without RAS mutations. However, EGFR inhibitors are ineffective in these patients, and tumor level of EGFR does not associate with response to therapy. We screened human colorectal tumors for EGFR-positive myeloid cells and investigated their association with patient outcome. We also performed studies in mice to evaluate how EGFR expression in tumor cells and myeloid cells contributes to development of colitis-associated cancer and ApcMin-dependent intestinal tumorigenesis. METHODS: We performed immunohistochemical and immunofluorescent analyses of 116 colorectal tumor biopsies to determine levels of EGFR in tumor and stroma; we also collected information on tumor stage and patient features and outcomes. We used the Mann-Whitney U and Kruskal-Wallis tests to correlate tumor levels of EGFR with tumor stage, and the Kaplan-Meier method to estimate patients' median survival time. We performed experiments in mice lacking EGFR in intestinal epithelial cells (Villin-Cre; Egfrf/f and Villin-CreERT2; Egfrf/f mice) or myeloid cells (LysM-Cre; Egfrf/f mice) on a mixed background. These mice were bred with ApcMin/+ mice; colitis-associated cancer and colitis were induced by administration of dextran sodium sulfate (DSS), with or without azoxymethane (AOM), respectively. Villin-CreERT2 was activated in developed tumors by administration of tamoxifen to mice. Littermates that expressed full-length EGFR were used as controls. Intestinal tissues were collected; severity of colitis, numbers and size of tumors, and intestinal barrier integrity were assessed by histologic, immunohistochemical, quantitative reverse transcription polymerase chain reaction, and flow cytometry analyses. RESULTS: We detected EGFR in myeloid cells in the stroma of human colorectal tumors; myeloid cell expression of EGFR associated with tumor metastasis and shorter patient survival time. Mice with deletion of EGFR from myeloid cells formed significantly fewer and smaller tumors than the respective EGFR-expressing controls in an ApcMin/+ background as well as after administration of AOM and DSS. Deletion of EGFR from intestinal epithelial cells did not affect tumor growth. Furthermore, tamoxifen-induced deletion of EGFR from epithelial cells of established intestinal tumors in mice given AOM and DSS did not reduce tumor size. EGFR signaling in myeloid cells promoted activation of STAT3 and expression of survivin in intestinal tumor cells. Mice with deletion of EGFR from myeloid cells developed more severe colitis after DSS administration, characterized by increased intestinal inflammation and intestinal barrier disruption, than control mice or mice with deletion of EGFR from intestinal epithelial cells. EGFR-deficient myeloid cells in the colon of DSS-treated LysM-Cre; Egfrf/f mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was reduced compared with controls. Administration of recombinant IL6 to LysM-Cre; Egfrf/f mice given DSS protected them from weight loss and restored epithelial proliferation and STAT3 activation, compared with administration of DSS alone to these mice. CONCLUSIONS: Increased expression of EGFR in myeloid cells from the colorectal tumor stroma associates with tumor progression and reduced survival time of patients with metastatic colorectal cancer. Deletion of EGFR from myeloid cells, but not intestinal epithelial cells, protects mice from colitis-induced intestinal cancer and ApcMin-dependent intestinal tumorigenesis. Myeloid cell expression of EGFR increases activation of STAT3 and expression of survivin in intestinal epithelial cells and expression of IL6 in colon tissues. These findings indicate that expression of EGFR by myeloid cells of the colorectal tumor stroma, rather than the cancer cells themselves, contributes to tumor development.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Srivatsa S, Paul MC, Cardone C, et al. EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. Gastroenterology. 2017. PMID: 28400195. doi:10.1053/j.gastro.2017.03.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。